[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359350-105":59,"doc-detail-359350-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","efficacy-and-safety-of-tepotinib-in-met-altered-non-small-cell-lung-cancer-a-meta-analysis","Efficacy and safety of tepotinib in MET-altered non-small cell lung cancer - a meta-analysis","","Efficacy and safety of tepotinib were evaluated through a systematic review and meta-analysis of six studies including 546 patients with MET exon 14 skipping mutations (METex14) or MET amplification in non-small cell lung cancer. Objective response rate (ORR) and disease control rate (DCR) were pooled as primary and key secondary outcomes, alongside progression-free survival (PFS), overall survival (OS), and safety. Tepotinib yielded an ORR of 52% and a DCR of 76%, with median PFS of 10.16 months and OS of 14.67 months. Subgroup analyses showed no significant ORR differences by MET subtype or treatment strategy, while common adverse events were mostly grade 1–2.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-tepotinib-in-met-altered-non-small-cell-lung-cancer-a-meta-analysis/359350/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-tepotinib-in-met-altered-non-small-cell-lung-cancer-a-meta-analysis/359350.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What outcomes were used to evaluate tepotinib efficacy and safety?","Question",{"text":113,"@type":114},"The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How effective was tepotinib overall in MET-altered NSCLC?",{"text":118,"@type":114},"The pooled ORR was 52% and the pooled DCR was 76%. Median PFS was 10.16 months and median OS was 14.67 months.",{"name":120,"@type":111,"acceptedAnswer":121},"Were there differences in response between METex14 and MET amplification or between therapy types?",{"text":122,"@type":114},"No significant ORR differences were found between METex14 (52%) and MET amplification (53%, p=0.905), or between monotherapy (51%) and combination therapy (56%, p=0.242).",{"name":124,"@type":111,"acceptedAnswer":125},"What adverse events were most common and how severe were they?",{"text":126,"@type":114},"The most common treatment-related adverse events were grade 1–2 peripheral edema (50%) and diarrhea (36%). Grade ≥3 adverse events were infrequent, including 8% for edema.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},359350,1790193976,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEfficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta‑analysis  \nJiayi Xiao1, Qinyi Cai1, Xinyuan Li2 & Degang Zhang1,3􀀍  \nMET exon 14 skipping mutations (METex14) or amplification drives a subset of non‑small cell lung cancer (NSCLC). Tepotinib, a selective MET tyrosine kinase inhibitor (TKI), has shown promise in early trials; however, comparative efficacy and safety data across MET‑altered subpopulations remain limited. This systematic review of six studies (546 patients) assessed the clinical outcomes ofTepotinibin METex14 or MET‑amplified NSCLC. The primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate (DCR), progression‑free survival (PFS), overall survival (OS), and safety. The pooled objective response rate (ORR) was 52%(95% CI: 48–56%) and a disease control rate (DCR) of 76%(95% CI: 72–80%) . Median PFS was 10.16 months, and median OS was 14.67 months. Subgroup analyses revealed no significant differences in ORR between METex14 (52%) and MET amplification (53%, p = 0.905) or between monotherapy (51%) and combination therapy (56%, p = 0.242). Common treatment‑related adverse events (TRAEs) were grade 1–2 peripheral edema (50%) and diarrhea (36%); grade ≥ 3 TRAEs were infrequent (8% for edema) . In conclusion, Tepotinib demonstrated comparable efficacy in METex14 and MET‑amplified NSCLC with a manageable safety profile. The PFS benefit of combination therapy warrants further randomized trials. These findings support Tepotinib as a valuable therapeutic option for MET‑altered NSCLC.  \nKeywords Tepotinib, non-small cell lung cancer, MET exon 14, MET amplification, meta-analysis  \nWorldwide, approximately 1.8 million deaths annually are attributed to lung cancer, which remains the leading cause of cancer-related mortality1,2. NSCLC accounts for approximately 85% of all lung cancer cases, and its global incidence continues to rise3,4. Treatment outcomes for NSCLC remain poor, with five-year survival rates declining sharply from 68% in stage IB to just 21% in stage IIIC. Moreover, most advanced-stage NSCLC cases acquire resistance to existing therapies, leading to disease progression5,6.  \nNSCLC comprises a genetically heterogeneous group of malignancies driven by various oncogenic alterations7. Several recurrent and potentially targetable oncogenes have been identified in NSCLC, including mutations in epidermal growth factor receptor (EGFR) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF), as well as chromosomal rearrangements involving ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) and anaplastic lymphoma kinase (ALK)8,9.  \nThe c-MET protein, encoded by the MET proto-oncogene, is a receptor tyrosine kinase expressed on cell membranes10. Constitutively altered MET pathway activation strongly propels malignant transformation, stimulates tumor cell progression as well as angiogenesis, increases tumor invasiveness as well as metastatic potential, and mediates resistance to MET tyrosine kinase inhibitors (TKIs)10, 11. MET signaling dysregulation typically arises through three distinct mechanisms: protein overexpression, MET gene amplification, and exon 14 skipping mutations (METex14)11. In NSCLC, MET exon 14 skipping mutations are established oncogenic drivers, whereas MET amplification and protein overexpression are generally associated with poorer prognosis12–17. It should be noted that MET gene fusions, though rare and actionable, were not included in the present analysis due to insufficient data in the identified studies.  \nGiven the extensive involvement of aberrant MET signaling in NSCLC pathogenesis and therapeutic resistance, MET has emerged as a promising therapeutic target. Over the past decade, several MET-targeted therapies—including TKIs and antibody-drug conjugates (ADCs)—have entered clinical evaluation18–24. METtargeting TKIs are classified int","cbCaiqL3jrnXF1xH","https://ap.wps.com/l/cbCaiqL3jrnXF1xH","pdf",3164188,"English","# Results\n## Literature screening results","[{\"question\":\"What outcomes were used to evaluate tepotinib efficacy and safety?\",\"answer\":\"The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.\"},{\"question\":\"How effective was tepotinib overall in MET-altered NSCLC?\",\"answer\":\"The pooled ORR was 52% and the pooled DCR was 76%. Median PFS was 10.16 months and median OS was 14.67 months.\"},{\"question\":\"Were there differences in response between METex14 and MET amplification or between therapy types?\",\"answer\":\"No significant ORR differences were found between METex14 (52%) and MET amplification (53%, p=0.905), or between monotherapy (51%) and combination therapy (56%, p=0.242).\"},{\"question\":\"What adverse events were most common and how severe were they?\",\"answer\":\"The most common treatment-related adverse events were grade 1–2 peripheral edema (50%) and diarrhea (36%). Grade ≥3 adverse events were infrequent, including 8% for edema.\"}]","Efficacy and safety of tepotinib in MET-altered non-small cell lung cancer - a meta-analysis | PDF",1790136740,25,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96aa8ff0cc01f6e8d1ea581bc2bc9d05.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43937f0c67755d34aa41ebd449834cb2.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e4bbcc9156416cbb947a47cf906bc72.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eae35ad190135f62562d8c1d8092f63f.webp",980,1287]